78
Participants
Start Date
October 5, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
March 3, 2028
Terpenes-Enriched CBD-Predominant Oil
Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD/THC: 280/10 mg per g) produced by Bazelet Group, Israel.
Placebo
Oral olive oil with added flavors to mimic the appearance, texture, and taste of the study drug, administered in two daily doses.
Terpenes-Enriched CBD Oil (THC-Free)
Oral cannabidiol (CBD; 7.2 mg/kg/day) and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD- 280 mg per g) produced by Bazelet Group, Israel.
RECRUITING
Shaare Zedek Medical Center, Jerusalem
Bazelet Nehushtan LtD.
INDUSTRY